Skip to main content

Day: November 13, 2025

NEXTENSA ACHIEVES SOLID RESULTS IN Q3

REGULATED INFORMATIONBrussels, 13 November 2025, 5:55 PMRESULTS ON Q3 2025HIGHLIGHTS  NEXTENSA ACHIEVES SOLID RESULTS IN Q3 In the third quarter of 2025 Nextensa maintained its strong momentum and achieved a clear increase in profitability. Net profit increased significantly, driven by a higher contribution of development activities, lower financing costs and a further strengthening of the balance sheet. Three significant transactions were completed in Q3 2025:Sale of Retail Estates. On August 28,2025, Nextensa has sold its entire 8.99% stake in the Belgian REIT Retail Estates, generating proceeds of €89.6 M. Sale of Monteco in Belgium on September 17, 2025: 100% of the shares of Monteco BV were sold jointly with ION for a valuation of €28 M. Sale of retail property in Ingeldorf, Luxembourg, on September 29, 2025, to the State of...

Continue reading

Bonduelle – Combined General Meeting of December 4, 2025: Statement of availibilty of documents

BONDUELLE  Head office: “La Woestyne” – 59173 Renescure – FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 ( Dunkerque Commercial and Companies Register) Villeneuve d’Ascq, November 13, 2025 Press release COMBINED GENERAL MEETING OF DECEMBER 4, 2025 Statement of availability of documents Shareholders are invited to attend the Combined General Meeting to be held on December 4, 2025 at 5 p.m. at the Company’s administrative headquarters, Rue Nicolas Appert, 59650 Villeneuve d’Ascq, France. The prior notice including the agenda and draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (hereinafter “BALO”) no. 128 of October 24, 2025, and the notice of meeting will be published...

Continue reading

JCDecaux strengthens leadership in São Paulo Metro with the renewal and extension of contract for Lines 1-Blue, 2-Green, and 3-Red, and the inclusion of Line 15-Silver through 2036

         JCDecaux strengthens leadership in São Paulo Metro with the renewal and extension of contract for Lines 1-Blue, 2-Green, and 3-Red, and the inclusion of Line 15-Silver through 2036 Paris, November 13th, 2025 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announces that its subsidiary JCDecaux Brazil has renewed and extended its advertising concession contract for the 1-Blue, 2-Green, and 3-Red lines of São Paulo Metro, along with the inclusion of Line 15-Silver, through 2036. The agreement, initially valid until 2030, has been extended to February 2036, adding six more years of operation and media management in São Paulo’s metro system. The contract renewal, as well as the expansion to Line 15-Silver, will take effect in February 2026. JCDecaux will be present in 63 metro stations...

Continue reading

Elis: Share capital increase reserved for employees “Elis for All 2025”

Share capital increase reserved for employees “Elis for All 2025” Saint-Cloud, 13 November 2025 The subscription period for the share capital increase reserved for Elis employees ended on 2 October 2025. 5.8% of employees in 20 countries chose to participate, either directly or via the Elis Group employee shareholding fund, in this operation, for a total subscription of nearly 15 million euros. Implemented by the Elis Supervisory Board on December 17, 2024 and by the Management Board on July 31, 2025, on the basis of a delegation of authority from the General Meeting of May 23, 2024 (France) and May 22, 2025 (foreign countries), the share capital increase allowed the Group’s employees to invest in Elis shares at a unit price of 16.86 euros, corresponding to the average opening price of the share from August 18 to September 12 2025,...

Continue reading

Ramsay Sante : Interim results at the end of September 2025

        PRESS RELEASE                Paris, 13th November 2025 Interim results at the end of September 2025 Revenue growth of 2.6% and Group EBITDA up 6.5% despite reduction in public funding; resilient operating performance Activity growth and cost control compensate constrained fundingUnaudited group revenue for the quarter ending 30 September 2025 increased by 2.6% to 1.21bn€ supported by activity volume growth, price indexation in Sweden and favourable foreign exchange movements. Revenue growth of 1.9% on a like-for-like basis. Acute hospitals admission volume growth in France and Sweden despite 1 less business day this quarter compared to the same period last year, reflecting sustained patient need for healthcare and the capacity of the group’s facilities to provide more quality care services in a competitive landscape. Unaudited...

Continue reading

Iceland Seafood International hf: Q1 2025 Uppgjör og fjárfestakynning

Áframhaldandi viðsnúningur, hagnaður fyrir skatta 590 milljónir ISK af reglulegri starfsemi Hagnaður fyrir skatta af reglulegri starfsemi nam 590 milljónum ISK (€4.1m) samanborið við 360 milljónir ISK (€2.5m) 9M 2024 sem er aukning um 230 milljónir ISK (€1.6m) Rekstrartekjur 9M 2025 námu 50,1 milljörðum ISK (€347.6m), sem er aukning um 11% eða 4,8 milljarða ISK (€33.6m) frá sama tímabili 2024 Framlegð fyrir 9M 2025 er 4,9 milljarðar ISK (€34.2m) samanborið við 4,1 milljarð ISK (€28.7m) á sama tímabili 2024 EBITDA fyrir 9M 2025 hækkaði um 55% í 2,0 milljarða ISK (€14.0m) frá 1,3 milljörðum ISK (€9.0m) 9M 2024 EBITDA síðustu 12 mánaða hækkaði um 0,9 milljarð ISK, í 3 milljarða ISK (€21.1m) frá 2,1 milljarði ISK (€14.8m) á Q3 2024 Hagnaður fyrstu níu mánuði eftir skatta er 360 milljónir ISK (€2.5m) samanborið við 216 milljóna ISK (€1.5m) tap fyrir...

Continue reading

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially best-in-class safety profile, once-daily administration, and ease of co-administration with common supportive medications in adult patients with R/R NPM1-mutated AML – – KOMZIFTI approval granted with no Boxed Warning related to QTc prolongation or Torsades de Pointes – – Kura Oncology will host a conference call on November 13, 2025, at 12:30 pm ET / 9:30 am PT – SAN DIEGO and TOYKO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq:...

Continue reading

Treasury Bill Auction Announcement – RIKV 26 0318 – RIKV 26 0520

Series RIKV 26 0318 RIKV 26 0520ISIN IS0000038016 IS0000038487Maturity Date 03/18/2026 05/20/2026Auction Date 11/17/2025 11/17/2025Settlement Date 11/19/2025 11/19/2025On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bills in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bills must be received by the Central Bank before 14:00 on the Settlement Date and the Bills will be delivered in electronic form on the same day. Further reference is made to the General Terms of Icelandic Treasury bills and General Terms of Auction for Treasury bills on the Government Debt Management website. For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.

Continue reading

Cenovus announces closing of MEG Energy acquisition

CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) is pleased to announce that its acquisition of MEG Energy Corp. (TSX: MEG) (MEG) was completed today. This acquisition strengthens Cenovus’s portfolio of long-life, low-cost oil sands assets, adding top-tier operations that are directly adjacent to the company’s Christina Lake asset. Total consideration paid by Cenovus included:$752 million of cash paid for 25.0 million MEG shares acquired through open market transactions. $3.44 billion of cash paid to MEG shareholders, other than Cenovus, under the terms of the agreement. 143.9 million Cenovus common shares issued to MEG shareholders, other than Cenovus, under the terms of the agreement. Approximately $800 million of estimated net debt assumed, on closing.“The addition of MEG assets...

Continue reading

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company“), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH“), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET).  Trading of the ordinary shares of the Company was halted, at the Company’s request, on November 13, 2025, from 9:00 a.m. (CET), in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares, each representing one new ordinary share of the Company with a nominal value of €0.01 (the “Offering“),...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.